11/3/2026

speaker
Conference Call Operator
Operator

Good afternoon and thank you for joining ZEVRA's third quarter 2026 financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website later today. The host for today's call is Nichol Ochsner, ZEVRA's vice president of investor relations and corporate communications.

speaker
Nichol Ochsner
Vice President of Investor Relations and Corporate Communications, Zevra

Thank you and welcome to those who are joining us. Today we will provide an overview of our recent accomplishments, followed by a review of our third quarter 2026 financial results. I encourage you to read our financial results news release, which was distributed this afternoon and is available in the investor section of our website. Before we begin the call, please note that certain information shared today will include forward-looking statements. Thank you for watching. Forward-looking statements are not promises or guarantees and are inherently subject to risks, uncertainties, and other important factors that may lead to actual results differing materially from the projections made and should be evaluated together with the risk factors section in our most recent quarterly report on Form 10-Q or annual report on Form 10-K and our other filings with the SEC. I'm pleased to welcome Zevra's management team members participating in today's call. Neil McFarlane, Zevra's president and chief executive officer, Josh Schafer, our chief commercial officer, and Justin Renz, our chief financial officer. Now, it's my pleasure to hand the call over to Neil.

speaker
Neil McFarlane
President and Chief Executive Officer, Zevra

Thank you, Nichol, and welcome to everyone joining our quarterly call this afternoon. Zevra is a purpose-driven company. Redefining what is possible and bringing life-changing therapies to people living with rare diseases. In rare disease, the path is complex, the needs are urgent, and the responsibility is significant. The people and families behind these needs are at the heart of what we do every day. Progress with the U.S. laws with myFIFA The first approved therapy for Niemann-Pick disease type C, or NPC, reflects the disciplined execution of our strategic plan and the determination, expertise, and commitment of our people. Together, we are building a trusted company with the capabilities and resolve to make a lasting difference. I'm pleased to share that total net revenue for the third quarter was $37.8 million, an increase of 45% compared to the third quarter of 2025. and net U.S. product revenue from myPIPA was $34 million. What was seen in the market suggests that it may be just the beginning, particularly as we strengthen our understanding of the NPC community in the United States, where an estimated 900 people are living with NPC, of whom 300 to 350 have been diagnosed. These estimates are derived from a study published in 2021 prior to any approved treatment for NPC. In the third quarter, we received 13 prescription enrollment forms, bringing the cumulative since launch to 197. In rare disease, the number of identified patients often grows over time. As awareness increases, more patients receive a diagnosis, and new therapies are approved. Josh will share more details on how our initiatives are driving patient identification, diagnosis, and treatment later in the call. Our commitment to realizing my wife's full potential and supporting the NPC community is driving our investment to expand patient access. In the second quarter, we published data from a multi-center, open-label pediatric sub-study evaluating treatment of NPC with Aromathemol in combination with Miglistat in infants six months to less than 24 months of age. The sub-study assessed safety and tolerability for up to 36 months of treatment and found that Arimocumal was well-tolerated with no new observed safety signals. On the heels of this, in the third quarter, we engaged with the FDA in a Type B meeting to explore the potential of extending the label to include infants less than 24 months of age. Based on the feedback, we expect to file an SNDA in the first quarter of 2027. Importantly, we believe MyPlypha is supported by a strong intellectual property portfolio. My plight was covered by patents listed in the Orange Book with expiration dates extending to 2041 and has U.S. orphan drug exclusivity for the treatment of MPC through 2031. These provide distinct layers of protection, regulatory-based exclusivity, and listed patent coverage. As mentioned on previous calls, we are also pursuing a potential patent term extension through the U.S. Patent and Trademark Office. and based on the current processing times, we now anticipate a decision from the USPTO in 2027. In the EU, the re-examination process for our Marketing Authorization Application, or MAA, for Aramocumal is underway by the Committee for Medicinal Products for Human Use, or CHMP. As part of the re-examination, a new Rapporteur and Co-Rapporteur have been appointed to lead the CHMP's evaluation. Additionally, an ad hoc expert group, or AHEC, will meet to review the data and provide their specialized scientific and clinical expertise. This is an important forum for experts in the field to offer perspectives that will contribute to the CHMP's procedural discussions. We believe the totality of the clinical and real-world evidence supports the clinically meaningful benefits observed in patients treated with Aromalcumal. The significant unmet need in Europe motivates us to keep working on behalf of people living with NPC, and we expect the CHMP's opinion in the fourth quarter. Due to the proximity of the AHANC and CHMP meetings, we will be brief in addressing questions regarding the ongoing procedure. Turning to our Global Expanded Access Program, or EAP, We remain steadfast in our commitment to the NPC community and supporting access to Arimathamol for eligible patients. Our global EAP has enrolled 134 patients and is comprised of compassionate use and named patient reimbursement programs. As previously discussed, quarterly reimbursement amounts fluctuate based on the timing and cadence of orders. Of note, this past quarter, we expanded the program to include an additional territory and continue to evaluate more opportunities to expand access to patients globally. Moving to our late-stage pipeline, Solipilol is being evaluated for the treatment of vascular Ehlers-Danlos Syndrome, or VETS. VEDS is a rare inherited connective tissue disorder caused by a change in the COL3A1 gene, leading to fragile walls in blood vessels and hollow organs, which can cause arterial rupture or dissection, among other complications. With our Phase III DISCOVER trial, we are confirming the ability of Solipilol, our selective adrenoceptor modulator, to reduce the mechanical stress on these tissues, thereby lowering the risk of major events. We enrolled 16 patients in the third quarter for a total of 72. As a reminder, the trial was designed with an interim analysis triggered at 28 events, and there have been four confirmed events through the end of Q3. We've discussed previously that we're focused on advancing the ongoing DISCOVER trial and are exploring options to accelerate the program by engaging with the FDA. Following a Type C meeting in the first quarter, we recently held a second Type C meeting to discuss a potential submission strategy with the addition of real-world data sets. In minutes to confirm next steps, we're developing a statistical analysis plan to include the retrospective data sets with the intent to have a follow-up discussion with the agency in the first half of 2027. Across our business, we remain focused on advancing key opportunities while maintaining a strong financial position. With more than $270 million in cash, cash equivalents, and investments as of the end of Q3, we believe we have the flexibility to pursue near-term opportunities with MyPiper in the U.S. and broadening access for patients in global markets, as well as advancing our development pipeline. I'll now ask Josh to review our commercial momentum. Josh?

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API